News from GMP area

Opened laptop and a hand

News from GMP Area


Cell-based gene therapy for the ALL treatment receives FDA approval, 2th of July 2017.

In the United States, the U.S. Food and Drug Administration (FDA) has approved a gene therapy for the first time at 30th of august. Henceforth, the treatment of acute lymphoblastic leukemia (ALL) in young patients up to 25 years is allowed, who couldn’t be cured with actual methods so far.

Even the FDA describes this as a historic step towards treating cancer and other life-threatening diseases with completely new approaches.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D.

Kymriah is based on the chimeric antigen receptor therapy known as CAR T-cell therapy. Patient's own T-cells are genetically modified in vitro using viral vectors in such a way, that they detect specific antigens (CD19) on the surface of the tumor cells, when given back to the patient.

This method of genetically modified autologous T-cell immunotherapy does not only attack the tumor directly, but activates the patient's own immune system to take targeted action against the cancer.

The safety and efficiency of the Kymriah method has been tested in a study with 63 ALL patients (children and young adults). The remission rate was 83% within the first three months. Despite severe side effects, which can arise and a lack of long-term prognoses, treatment with Kymriah is a great opportunity for young patients with ALL who hasn’t had hope any longer.


Further information

Dr Claudia Papewalis is giving a GMP for ATMP training


If you want to know more about the regulatory requirements requested for manufacturing ATMPs, contact our experts or take part at one of our internal GMP training courses.

A scientist is looking at t-cells visible at a computer screen

GMP-compliant manufacturing process

Valicare supports start-ups like polybiocept in transferring cell-culturing methods developed at the laboratory into a GMP-compliant manufacturing process. Check the press release and get an overview about our GMP for ATMP services.

cell culture, ATMPs

„Guidelines on Good Manufacturing Practice (GMP) specific to Advanced Therapy Medicinal Products”

On 22th of November 2017 the European Commission adopted the "Guidelines on Good Manufacturing Practices (GMP) specific to Advanced Therapy Medicinal Products".